FBF510B1-3629-4FB9-BF9C-5BE689827DAC
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 59.00131406044678
- age_years
- 48
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.671
- INTERFERON_GAMMA_RESPONSE+0.652
- ALLOGRAFT_REJECTION+0.606
- IL6_JAK_STAT3_SIGNALING+0.550
- NOTCH_SIGNALING+0.522
- TNFA_SIGNALING_VIA_NFKB+0.510
- INFLAMMATORY_RESPONSE+0.499
- TGF_BETA_SIGNALING+0.448
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.442
- APOPTOSIS+0.425
Top 10 suppressed
- SPERMATOGENESIS-0.397
- KRAS_SIGNALING_DN-0.277
- PANCREAS_BETA_CELLS-0.223
- UV_RESPONSE_DN-0.131
- MYOGENESIS-0.120
- APICAL_JUNCTION-0.110
- ANGIOGENESIS-0.090
- ANDROGEN_RESPONSE-0.036
- PROTEIN_SECRETION-0.035
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.019
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.925 |
| 2 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.912 |
| 3 | 165395C6-1028-49DF-B15D-4D8064D00995 | — | — | 0.906 |
| 4 | 928D2F99-A86B-47CA-A961-A8CAE7B44E78 | — | — | 0.898 |
| 5 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.898 |
| 6 | MNG57 | — | — | 0.897 |
| 7 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.893 |
| 8 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.893 |
| 9 | F1D36132-F3C3-47BB-A41F-A10DF40B69D1 | — | — | 0.892 |
| 10 | 1C62E679-3A4E-4D10-8BFB-5BFBF2A3B4B6 | — | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.671 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.652 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.606 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.522 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.499 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.448 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.442 | Inavolisib | — uncovered |
| APOPTOSIS | 0.425 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.409 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.402 | Idelalisib | — uncovered |
| COMPLEMENT | 0.386 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.323 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.317 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.303 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.299 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.286 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.266 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.259 | Idelalisib | — uncovered |